The clonal and mutational evolution spectrum of primary triple-negative breast cancers

By Sohrab P. Shah, Andrew Roth, R. Goya, A. Oloumi, G. Ha, Yongjun Zhao, G. Turashvili, Jiarui Ding, Kane Tse, Gholamreza Haffari and 49 more. Nature, 2012

1,975 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/5301866296faac1aab3a0d80b4abb768b488ef76

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

SciClone: Inferring Clonal Architecture and Tracking the Spatial and Temporal Patterns of Tumor Evolution (2014, methodology): “As with other tools [6,11,22,30], regions of CNA and LOH are provided as inputs after having been inferred from whole-exome sequencing (WES, e.g., via ASCAT [22,34], cn.MOPS [35–37], or VarScan 2 [38]), whole-genome sequencing (WGS, e.g., via HMMcopy/ APOLLOH [11,39] or VarScan 2 [38]), or SNP array”
Cellular mitophagy: Mechanism, roles in diseases and small molecule pharmacological regulation (2023, background): “In some breast cancers, the fragile region of FRA6E containing PARK2 is often absent, which also supports the inhibitory effect of Parkin on tumor cells [93].”
Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. (2015, background): “In contrast to ccRCC, in breast, ovarian, pancreatic, and esophageal cancers, TP53 mutations have been found generally to be early events (Bashashati et al., 2013; Nik-Zainal et al., 2012b; Shah et al., 2012; Weaver et al., 2014; Yachida et al., 2010).”
Comprehensive molecular portraits of human breast tumors (2012, neutral): “12 were also observed at a similar frequency in our TNBC subset ( Myo3A not present here); of those five, three passed our test as a significantly mutated gene in TNBCs (Supplementary Table 2).”
Recent advances in therapeutic strategies for triple-negative breast cancer (2022, result): “The frequency of genomic alteration in PI3K is second after TP53 in TNBC, and interestingly, it is significantly rarer (~ 10%) [45] in TNBC compared to other breast cancer subtypes (34.”